< Journal Club >

제목: 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

일시: 11월 29일(화) 07:30 am

발표자: R2 채예린

Moderator: Pf. 박영목